EICHOR
● Recruiting
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
Condition: Cancers · Sponsor: NucMito Pharmaceuticals Co. Ltd.
About this study
This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Talk to the study team
COO · 86-592-7829029 · ClinicalDevelopment@nucmito.com
Always discuss trial participation with your own doctor first.
Locations (3)
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
| Sun Yat-sen University Cancer Center (SYSUCC) | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07292038